Personalized Intravenous (IV) Insulin Therapy to Achieve the Safest Patient Outcomes
For patients with elevated glucose levels in the critical care setting, IV insulin is the recommended method of achieving target glucose levels. The problem is IV insulin protocols can be difficult to follow and time-consuming for nursing staff, especially if using paper protocols.
To avoid medication errors and ensure patients are receiving the safest insulin dose requires a systematic approach that eliminates risks and personalizes insulin doses for each patient.
EndoTool IV, A Precision Insulin Dosing Software Application
Improves Compliance and Reduces the Risk of Insulin Dosing
EndoTool IV offers a straightforward software solution to recommend a personalized insulin dose when intravenous insulin is administered to manage hyperglycemia.
An Advanced Algorithm Designed to Treat Each Patient Uniquely
Using a non-linear dosing model and machine-learning approach, EndoTool IV
translates past data points into an individual physiological model for each patient.
Rather than using a fixed multiplier or linear protocol, EndoTool IV uses proprietary technology to model, predict and adapt each patient’s dosing recommendation. The dosing recommendation is based on 11 patient-specific factors, including the presence of steroids, kidney function and residual insulin.
Estimated Residual Extracellular Insulin
Similar in concept to the subcutaneous “insulin on board,” Estimated Residual Extracellular Insulin (EREI) refers to residual insulin present in a patient’s body from previous doses. EndoTool IV contains an algorithm that triggers the software to down regulate an insulin dose to adjust for residual insulin circulating in the blood stream to help prevent hypoglycemia.
Designed to Treat All Hyperglycemia
EndoTool IV is designed to treat all patient demographics, including patients as young as 2 years of age and weighing at least 12 kg. The system provides personalized dosing recommendations based on the patient’s diagnosis, type 1 diabetes, type 2 diabetes, gestational diabetes, or non-diabetes with stress induced hyperglycemia, and provides optional EndoX modes of therapy to support providers with the appropriate insulin regimen for diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic nonketotic syndrome (HHS).
EndoTool IV does not require tedious and time-consuming carbohydrate counting, and more importantly, it does not assume that carbohydrates have been consumed by a patient. Instead, EndoTool IV uses a patient’s actual response to carbohydrate or dextrose intake and the current blood glucose level to recommend next steps in treatment. A meal timer feature simplifies meal-time dosing by reminding the caregiver to simply take a blood glucose reading after the specified meal time, so that the software may continue to accurately model the patient’s treatment.
Transition to Subcutaneous Insulin
Transitioning from intravenous to subcutaneous insulin therapy is seamless with the EndoTool Glucose Management System. EndoTool IV can provide patient-specific transition orders from IV insulin to EndoTool SubQ for subcutaneous insulin therapy or to any other defined protocols from the organization.
Aligned with your Hospital’s Standards and Practices
- EndoTool IV is flexible and customizable with recommended parameters that can be modified down to the unit level, to support the organization’s standard of practice and internal policies.
- The system is capable of full integration with your Electronic Medical Record
- Your team is supported 24/7/365 by EndoTool IT and Clinical Experts
- Designated users can track performance and dive deeper with advanced analytics